SCHEMBL14715334

SCHEMBL14715334

Cc1cccc(CNC(=O)C(NC(=O)c2ccc(-c3ccc(OCCO)cc3)cc2)C(=O)NO)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 5/20 0.43
CHRNB4 P30926 5/20 0.43
CHRNA3 P32297 5/20 0.43
CHRNA4 P43681 5/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
HSD17B10 Q99714 2/20 0.43
LMNA P02545 2/20 0.43
TP53 P04637 2/20 0.43
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HPGD P15428 1/20 0.41
ALDH1A1 P00352 1/20 0.41
PKM P14618 1/20 0.40
PPARG P37231 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
KLKB1 P03952 1/20 0.39
ITGB3 P05106 1/20 0.38
ITGAV P06756 1/20 0.38
ROCK2 O75116 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14715017 0.86 HPGD (0.55) NPC1RAB9AHSD17B10LMNAMAPT
SCHEMBL14715050 0.83 NPC1 (0.41) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL14715049 0.82 PPARG (0.51) PPARGHRH3
SCHEMBL14714539 0.81 HPGDS (0.42) HSD17B10HPGDALDH1A1PPARGHRH3
SCHEMBL14715019 0.81 HRH3 (0.42) HSD17B10HPGDALDH1A1PPARGHRH3
SCHEMBL14715383 0.81 PPARG (0.40) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL14714737 0.81 KLKB1 (0.51) NPC1RAB9AHPGDKLKB1ROCK2
SCHEMBL14715222 0.81 PPARG (0.39) HSD17B10HPGDALDH1A1PPARGHRH3
SCHEMBL14715425 0.81 PPARG (0.50) PPARGHRH3
SCHEMBL14714981 0.80 ANPEP (0.49) NPC1PPARGHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2562155-B1 HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO LTD (JP) 2019-06-05 EP disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
EP-2562155-A1 NOVEL HYDROXAMIC ACID DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 CHRNB2 4866/4885CHRNB4 4879/4885CHRNA3 4863/4885
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 CHRNB2 4866/4885CHRNB4 4879/4885CHRNA3 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.